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Abstract
Rheumatoid arthritis is the most prevalent autoimmune disease. Rheumatoid arthritis (RA) has
no cure, and the direct cause of the disease is still unknown. The two leading hypotheses
concerning its etiology are based on the effects of HLA-DRB1 gene expression, and cigarette
smoke. Conjunctively, the use of vaping devices amongst adolescents has increased significantly
since introduced in 2007. There is no long-term data on the effects of e-vapor and its aerosols on
bodily health. Cigarette smoke is the most noteworthy environmental factor contributing to RA
therefore the question is raised as to whether or not vaping relates to rheumatoid arthritis
susceptibility. This extended literature review focused on the current knowledge of RA, as well
as cigarette smoke and its role in rheumatoid arthritis pathogenicity. An experimental proposal is
also described which analyzes the effects of e-vapor on collagen induced arthritis mouse models.
HLA-DRB1 gene expression, autoantibody proliferation and rheumatoid arthritis symptomology
were investigated in acute and chronic RA mouse models. Ideally, these experiments would
clarify the potential effects of vaping in regard to RA and provide significant insight for future
generations.

Keywords: Rheumatoid arthritis, environmental factors, vapor, cigarette smoke, HLA-DRB1
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INTRODUCTION
Rheumatoid arthritis is a chronic, inflammatory autoimmune disease which develops
within the joints and can lead to life-threatening complications throughout the body. Currently,
as with many autoimmune diseases, there is no cure for rheumatoid arthritis (RA). Pain
management and immunosuppressive pharmaceuticals are the only options to which the over 23
million RA patients can turn.1 Approximately one percent of the adult population of the world
experiences RA which makes it the most common form of rheumatic diseases.1 This equates to
approximately 78,000,000 individuals. RA has no known cause, but current hypotheses note the
potential roles of gene expression coinciding with environmental factors such as cigarette
smoking (CS), obesity, age and gender.2
Rheumatoid arthritis begins its path of destruction by attacking the synovium, then
disseminate into the surrounding joints and bone causing massive tissue degradation.3 It first
attacks the synovium- a flexible sac of fluid surrounding joints. Originating within small joints,
RA then spreads to larger joints, and, in severe cases, certain organs.1,2 Some joints that are
affected as this disease progresses include the wrists, elbows, and knees eventually leading to
effects on organs such as the skin, eyes, heart, blood vessels, kidney, spleen and lungs.2,3 Fluid
build-up, inflammation, deterioration, pain, and loss of joint mobility, are common symptoms of
RA.2
There are several forms of arthritis, therefore it is critical to note that RA is different from
alternative forms of arthritis such as osteoarthritis because it affects the proximal interphalangeal
(PIP) and metacarpophalangeal (MP) joints, rather than the distal joints of the hands and feet.2
This inflammation and destruction of the proximal joints leads to deformities such as the swan
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neck and boutonniere, as shown in Figure 1
which lead to a severe decrease in quality of
life and loss of mobility given their
characteristic misshapenness, swelling and
degradation.24
Biologically, it is thought that
rheumatoid arthritis is triggered by changes
in the innate and adaptive immune systems
which leads to autoantibodies such as

Figure 1: Degradation of RA joint. Depicts the notable
deformations such as swan neck and boutonniere in the
fingers caused by RA.24

Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPAs) being produced
from B-cells. These autoantibodies are then allowed to circulate through the body thus eliciting a
self-reactive response by cytotoxic T-cells (TC).2,5 These autoantibodies begin to attack the
synovial membrane due to an error in differentiating self from foreign antigens which leads to
inflammation and fluid build-up causing joint and cartilage erosion common with RA.5 A
definitive causation of RA (prior to its measurable effects on the body) is still unknown, but it is
thought to be affected by both an increase in genetic susceptibility and environmental factors,
particularly cigarette smoking.2,4
Cigarette smoking, as mentioned previously, is the number one environmental contributor
to rheumatoid arthritis.6 Current data has established there is a strong correlation between CS
exposure and RA development; specifically via the HLA-DRB1 gene responsible for
autoantibodies RF and ACPA production.6 CS is associated with HLA-DRB1 activation, and
therefore relates to the upregulation of autoantibody production.6 Notably, not all individuals
who smoke traditional cigarettes experience an increase in autoantibody production- this is
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thought to be due to the duration and intensity with which the individual smoked, though
duration is most critical for RA onset, rather than intensity alone. 6 Regardless of autoantibody
proliferation rates, however, CS is associated with an increased risk of RA development.6 Many
studies have indicate the environmental and genetic impacts of CS on RA, however, few have
concerned the effects of e-vapor.
E-vapor, otherwise known as vaping, is a fairly new form of e-cigarette popular amongst
adolescents and young adults. Over 16 million adolescents vape within the United States since
the beginning of 2020 which is a drastic increase from 2018 statistics listing 1.3 million
adolescents actively vaping.7 This robust market offers many options to consumers in order to
vape based on their individual preferences. For instance, vaping machinery varies greatly in
design and purpose- including but not limited to ohm power, heat capacity of the coils, density of
vapor expelled, flavoring, and the sizes of the modules. Due to the large variability amongst the
types of vape available, few studies have been conduction on its health implications, either
negative or positive. With the large array of vape modules on the market, standardizing
experimentation has posed as an obstacle within laboratory settings. The Center for Disease
Control states that smokers who utilize vaping as a way to quit smoking in the traditional
manner, due to the hypothetical decreased levels of carcinogens in vaping products.8 However,
opposing studies hypothesize that vaping is just as severe to one’s health as CS, if not more.6
This stark contrast of data epitomizes the current understanding of vaping. Ultimately, there is
not scientific, nor popular opinion, consensus on the effects of vaping. In fact, most of the
literature available on the subject are based on the legislation surrounding how vape companies
target minors via advertising, as well as public perception of vape.7,8 The studies that have been
released concerning vape and human health, indicate vaping leads to high rates of reactive
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oxygen species in the body, as well as negative repercussions on lung health.9,10 The long-term
effects of vape have yet to be uncovered. Therefore, there is an immense need for studies focused
on the complexity of e-vapor. Since vaping is tremendously popular amongst youth and young
adults, the need has quickly arisen to study longitudinal effects of vaping. Given the
contributions to RA CS has, there may prove to be a strong correlation between vape and the
onset of rheumatoid arthritis later in life. Studies must be pursued in order to ascertain the
possible effects of vaping on RA to save a future generation from what may be a fairly avoidable
and severe autoimmune disease.
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METHODOLOGY
Research Methodology
Since the data concerning the subject matter of Rheumatoid Arthritis and cigarette
smoking is vast, but the information pertaining to RA and e-vapor is sparse, the most effective
route of methodology is an extensive review of the literature. Databases such as PubMed,
EBSCO, Academic Search Complete and others were utilized in order to closely study the
research of those who have paved the way in this content area. Furthermore, a proposed
laboratory experiment concerning the effects of e-vapor on rheumatoid arthritis mouse models is
disclosed beginning on page 40. It is critical to note that though this experiment is theoretical, it
is believed to be an effective summation and comparison of the current data on cigarette smoke,
e-vapor and their effects on the potential induction of rheumatoid arthritis and its pathogenicity,
particularly in adolescents.
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REVIEW OF THE LITERATURE
The Immune System
The immune system is a highly efficient and complex network present throughout the
human body. This elaborate system of checks and balances for the overall health of the body is
made possible by the intricate relationships, chain reactions and signaling abilities between
millions of immune cells.9 Rheumatoid arthritis is characterized by the malfunction of said
immune cells.10 RA occurs when there is a change from immune cells being protectors of
nonpathogenic tissue to agitators against the body, in particular cells that make up the synovial
membranes surrounding joints.10 This phenomena is thought to occur due to autoantibody B
lymphocytes in conjunction with T-cells (T-lymphocytes) becoming proinflammatory effector
cells instead of regulatory T-cells (Treg) thus causing a chain reaction response in the immune
system.10 Treg cells function to suppress the responses of other T-cell subsets (such as
proinflammatory TH1 and TH2 cells), antigen presenting cells and B-lymphocytes.11 These
autoreactive (self-attacking) T-cells partner with autoantibodies released from B-cells thus
eliciting a destructive immune response leading to joint degradation, inflammation and the
eventual replacement of healthy flexible tissue with dense fibrous tissue.10 Before the RA
pathogenicity can be fully understood, however, one must comprehend the key players in a
healthy immune system.
Antibodies
Antibodies, otherwise known as immunoglobulins (Ig), are the linchpin to the immune
system. Without these proteins, the body would be largely unable to recognize foreign pathogens
such as bacteria, viruses and foreign entities.11 There are two broad types of lymphocytes
immune cells, T-lymphocytes, also called T-cells, and B-lymphocytes known as B-cells.11 B-
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cells generate billions of unique forms of themselves and antibodies that correlate with their
characteristics in order to ward of infection.11 This diversity is crucial to the adaptive immune
system which learns to identify specific pathogens by experiencing multiple exposures to said
molecules, thus creating memory within the immune system.
There are five broad categories of immunoglobulins, IgA, IgD, IgE, IgG and IgM.11 Each
type of Ig correlates with one specific type of antigen-binding site.11 IgM is known for its role on
naïve B-cells which is further explained in the following paragraphs.11 IgA is common within the
mucosal lining and activates mucosal tissue responses to pathogens.12 IgE activate granulocytes
(such as mast cells, eosinophils and basophils) and primarily respond to allergens or parasites
within the body.12 IgD is not well understood but potentially assists in process of B cell
maturation.12 IgG is famous for its role in binding to Fc𝛾 receptors on T cells which are then
activated to respond and assist mature B-cells (also known as effector or plasma cells).11 IgG is
an opsonin which is a biochemical marker that signals for phagocytosis.11 Its role is critical to the
negative effects of RA, but it may also play a role in the prevention or treatment of rheumatoid
arthritis.12 IgG is the most noteworthy Ig for RA, and while the other antibodies are significant
within the body they have shown little direct correlation with RA for the purpose of the
discussion on hand.
Antibodies have exclusive relationships with antigens. A specific antibody will only bind
to a specific antigen.11 Antigens, or molecules that cause an immune response, can range
anywhere from a sliver of wood in an index finger to cancerous cells, and nearly anything in
between. In ideal situations, the immune system is able to detect, label and bind with each
specific enemy it faces in order to quickly and effectively terminate the threat.
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Each B-cell generates an antibody with one type of receptor for a specific antigen.11 Prior
to releasing an antibody army against pathogens though, each naïve B-cell within the bone
marrow must undergo a maturation process so it learns to recognize foreign invaders from
healthy, nonpathogenic, “self,” cells.11 IgMs are presented on the B-cell surface as a way for the
immature B-cell to identify a new threat from a variety of cells it faces and then allows it to
signal for specific immune responses.11 Upon binding with a foreign substance, as a B-cell
generates its first antibodies aside from IgM, the antibodies are inserted into the plasma
membrane.11 With 105 receptors on a B-cell, the maturing B-cell with its respective antibodies is
able to quickly signal through intracellular pathways when an antigen binds to any of its antigenbinding sites.11 Once an antigen is bound to the immature naïve B-cell, the B-cell multiplies and
differentiates into an antibody-secreting effector cell with the assistance of a helper T-cell (Th) in
Figure 2. 11
Figure 2: Activation and Class-Switching of B-cells. This indicates the complex relationship
antigen presenting cells, T-helper cells, active T cells, and B-cells have with one another in
order to elicit a healthy immune response.12

9
Specific cytokines are then released in response to the B-cell/T-cell partnership.11 Once
the B-cell has matured, the antibodies it makes are secreted rather than bound to the plasma
membrane since the B-cell has learned to recognize pathogen from self-cells and is now
considered an active plasma cell.11 If a B-cell is unable to differentiate between self and
pathogenic material, it is destroyed or deactivated unless it evades those actions.11
Antibody Structure
B-cells generate antibodies.11 Antibodies are able to bind to antigens due to their unique
molecular structure and binding regions.11 Each antibody is a “Y”-shape consisting of two heavy
polypeptide chains and two light chains, as shown in Figure 3.11
The heavy chain gives an
antibody a name- one of any of the
five classes mentioned prior (IgA,
IgD, IgE etc.).11 The hinge regions
between the “Y” arms and the tail (Fc
region) of the “Y” are uniquely
capable of creating more or less space
between the antigen binding sites in
order to optimize binding affinity.11
The antigen binding sites are at either
end of the “Y” arms and between the
N-terminal regions of one light chain
and one heavy chain.11 Although there
is a pair(s) of antigen binding sites, it

Figure 3: Antibody Structure. Antibodies consist of two light
chain and two heavy chain regions.12 Additionally, the ends
of the antibody where the antigen binding site is located are
known as variable regions while the tail of the antibody is
the constant region.11
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is necessary to note this does not change the one-to-one binding relationship of an antibody to a
specific antigen.11 The stem of the “Y” is the portion of an antibody other immune cells, like Th
cells, read in order to determine how they should respond to the antigen the antibody is
holding.11
Complement
The immune system functions in two broad but intertwined categories: innate and
adaptive.12 The complement system is most often considered a product of the innate immune
system.12 It is a way for antibodies, a component of the adaptive immune system, and phagocytes
such as macrophages, monocytes and granulocytes to enhance their collaboration.12 This
partnership allows them to rid microbes and damaged cells from the body.12 Within this process
four major functions are executed: lysis of infectious organisms, activation of inflammation,
opsonization and immune clearance.12 Lysis and apoptosis is often achieved by phagocytes, short
lived neutrophils, and longer living monocytes or macrophages which “digest” cell matter.13 The
act of degradation via any of these cells, depending on the signals received, can quickly lead to
inflammation.13 Inflammation by definition is the accumulation of fluid and cell matter caused
by blood vessel dilation.13 This is a positive result of the body attempting to fight off an attack,
thus signaling for an influx in white blood cells however, when inflammation is chronic it leads
to serious repercussions— such is the case in RA.12 Opsonization is a biochemical marker which
is brought on most frequently by IgG on plasma cells and indicates the need for antigen
destruction by phagocytosis.12
In order for cells to recognize the need for phagocytosis, there must be T-cell activation,
which is triggered by antigen presentation.14 The adaptive and innate immune systems work via
B-cells and other antigen presenting cells (APCs) such as macrophages and dendritic cells (DC),
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respectively expressing class II MHC molecules while all nucleated cells express MHC class I.14
MHC I signifies two main roles. Firstly, it exclusively signals for cytotoxic T-cells that kill
threats on contact. Secondly, MHCI is the indication to immune cells that the cell it is on is
“self,” therefore cells that have MHCI on their surfaces are not destroyed by natural killers
(NKs).13 Major histocompatibility complex (MHC II) is required for T cells to read an antigen.
This differs from B cells which can bind directly to a pathogen, in that rather than displaying a
whole antigen on its surface, MHCII display small peptides of an antigen on the cell surface for
T-cell receptors.15 MHC II recruits helper T-cells which positively assist B-cells by aiding in
their release of antibodies.14,15 In autoimmune diseases where MHC II malfunctions, only MHC I
is able to signal which leads to extensive cellular death brought on by the excessive presence of
cytotoxic CD8+ T-cells.15
As opposed to cytotoxic T-cells, when helper T-cells are activated they divide and secrete
cytokines that can regulate and assist in the immune response.14 They are able to signal for white
blood cells to respond to the infected area, thus increasing symptoms of an immune response, but
not exclusively calling for immediate phagocytosis of threatening cells.16 Research has indicated
that helper T-cells as well as effector cytotoxic (TC) act within the synovium of joints of RA
patients.13 In the synovium of RA patients, Th and TC cells signal for increased cellular response
from immune cells, such as macrophages, B-cells and cytotoxic T cells, and destroy healthy cells
perceived to be pathogenic, respectively.13 Once cytotoxic T-cells are activated, they are effector
cells which target and kill any other cell that has the same pathogen within it.15
Normally, the body screens for self-reactive T-cells during their development in the
thymus.15 However, self-reactive T-cells either by-pass checkpoints during their maturation
process or mutate later to become self-reactive.15 Self-reactive T-cells are able to independently
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bind strongly to self MHC complexes rather than requiring the assistance of CD4/8 coeffectors.15 Since the T-cell does not require a co-effector, it is able to bind to any cell that is
displaying self MHC, rather than self MHC that is simultaneously displaying a foreign
pathogen.15 This upheaval in the T-cell binding affinity leads to a heightened immune response
due to the increase in apoptosis.15 Chronic inflammation caused by the cytokines released, as
well as the flood of white blood cells signaled to the area due to the cytotoxic cell destruction,
leads to the symptoms of RA.13 A clear route from acute to chronic inflammation has not yet
been discovered, but chronic inflammation is associated with an increase in macrophages and
lymphocytes to the site of infection.17 Long-term inflammation signals the body to have
increased blood flow/vasodilation which naturally increases the migration of white blood cells to
the area where antibodies are signaling for a response. This response becomes a vicious cycle
that perpetuates the devastation of RA.18
Healthy immune response ordinarily begins with neutrophils because they are able to
signal for inflammatory response, but these cells quickly die to prevent prolonged signaling.18 In
rheumatoid arthritis, due to persistent inflammatory signals, longer living white blood cells
(WBC) such as macrophages and lymphocytes have to respond to the inflammation and cell
deaths since the neutrophil population becomes depleted.18 The normally healthy process of a
quick and efficient response to pathogens instead leads to long-term inflammation and
degradation due to the prolonged presence of macrophages, lymphocytes and the cells they
signal (B and T-cells).18 In turn, degradation leads to the replacement of healthy tissue around
the bones to be replaced with much stiffer connective tissue built by fibroblasts since the
synovium is degrade to such large degrees.18
Cytokines
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Cytokines are signaling molecules that act as regulators of temperature, inflammation,
neutrophil mobilization and many other responses in the immune system.16 There are
approximately 50 types of cytokines known in the human body, each with its role and regulatory
ability.16 Early RA is thought to be affected by eleven different cytokines, including cytokine
tumor necrosis factor alpha (TNFɑ) and interleukin-6 (IL-6), although this data is tentative.16
TNF and IL-6 are both pro-inflammatory cytokines which by definition increase inflammatory
response and increase osteoclast differentiation in the joints, specifically.16 Together, these two
cytokines simultaneously increase pressure within the synovium around joints and increase the
population of cells that degrade bone.16 Also key to rheumatoid arthritis are T-helper 17 (Th17)
cells.19 Th17 cells produce cytokines interleukin-17A (IL-17A), IL-17F and IL-22.19 IL-17A and
IL-17F are known to recruit and activate neutrophils and stimulate other cells to produce
inflammatory cytokines such as IL-6.19 This combination of Th17 cell subtypes is thought to be a
cause to the chronic inflammation within the joints of RA patients.19
Autoantibodies
Autoreactive T-cells interact with autoantibodies released from self-reactive B-cells.12
Autoantibodies are antibodies that have become self-reacting, rather than self-protecting.20
Ordinarily, autoantibodies are only found in minute amounts as IgM molecules, however, large
amounts of autoantibodies cause detriment to the body.20 Autoantibodies that undergo mutations
are no longer non-antigenic, therefore they trigger defensive immune reactions against selfcells.21 The chemical trigger which leads to the change from healthy antibodies from B-cells to
autoantibodies is largely undiscovered. Alberts, Johnson and team showed great promise in their
recent study indicating how Rho, a small GTPase, may signal for negative changes to B and Tcell development, activation proliferation differentiation and migration.14 Regardless,

14
mutation(s) within IgM antibodies become IgG autoantibodies- known to be more widespread
and have specific adhesion properties compared to healthy IgM which do not have specific
adhesion properties.21 This change thus leads to a broader ability to inaccurately bind to self-cells
and elicit an unnatural and detrimental immune response. ACPA and RF are two autoantibodies
commonly present in preclinical disease onset.3 As mentioned within the Biomarkers portion of
this discussion, these autoantibodies have been utilized as early indicators that RA may develop,
and its severity may be predicted.2 Also, the increased production of these autoantibodies is
strongly correlated with the environmental factor of cigarette smoking.1 Therefore, recent
literature has begun to explore the possible genetic pathways affected by cigarette smoke that
may lead to this increased proliferation of autoantibodies.6
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Rheumatoid Arthritis
Rheumatoid Arthritis
Rheumatoid arthritis is a chronic, inflammatory autoimmune disease which develops
within the joints and can lead to life-threatening complications throughout the body. Currently,
as with many autoimmune diseases, there is no cure for rheumatoid arthritis (RA). Pain
management and immunosuppressive pharmaceuticals are the only options to which the over 23
million people affected by RA can turn.1 Approximately two percent of the adult population of
the world experiences RA which makes it the most common form of rheumatic diseases.1 RA has
no known cause, but current hypotheses note the potential roles of gene expression coinciding
with environmental factors such as cigarette smoking (CS), obesity, age and gender.2
Rheumatoid arthritis begins its path of destruction by attacking the synovium, then creeps
its way into the surrounding joints and bone causing massive tissue degradation.3 It first attacks
the synovium- a flexible sac of fluid surrounding joints. Originating within small joints, RA then
spreads to larger joints, and, in severe cases, certain organs.1,2 Some joints that are affected as
this disease progresses include the wrists, elbows, and knees eventually leading to effects on
organs such as the skin, eyes, heart, blood vessels, kidney, spleen and lungs.2,3 Fluid build-up,
inflammation, deterioration, pain, and loss of joint mobility, are common symptoms of RA.2
There are several forms of arthritis, therefore it is critical to note that RA is different from
alternative forms of arthritis such as osteoarthritis because it affects the proximal interphalangeal
(PIP) and metacarpophalangeal (MP) joints, rather than the distal joints of the hands and feet.2
This inflammation and destruction of the proximal joints leads to deformities such as the swan
neck and boutonniere, as shown in Figure 4 which lead to a severe decrease in quality of life and
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loss of mobility given their characteristic misshapenness, swelling and degradation.2

Boutonniere deformity
Swan neck deformity

Figure 4: Boutonniere and swan neck deformities
common to RA joint degradation2
Biologically, it is thought that rheumatoid arthritis is triggered by changes in the innate
and adaptive immune systems which leads to autoantibodies such as Rheumatoid Factor (RF)
and Anti-Citrullinated Protein Antibodies (ACPAs) being produced from B-cells. These
autoantibodies are then allowed to circulate through the body thus eliciting a self-reactive
response by cytotoxic T-cells (TC).2,5 These autoantibodies begin to attack the synovial
membrane due to an error in differentiating self from foreign antigens which leads to
inflammation and fluid build-up causing joint and cartilage erosion common with RA.5 A
definitive causation of RA (prior to its measurable effects on the body) is still unknown, but it is
thought to be affected by both an increase in genetic susceptibility and environmental factors,
particularly cigarette smoking.2,4
Etiology
The etiology of rheumatoid arthritis is still unknown, however, there are several factors
that lead to an increased risk of developing RA. Gender, age, obesity, genetic susceptibility,
environmental factors and biomarkers all can indicate vulnerability to developing this
autoimmune disease.1 Research has unanimously concluded that the most vulnerable population
by far is middle-age women— notably, there seems to be few differences in susceptibility when
the ethnicities of middle-age women are considered.1
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Beyond one’s sex increasing the risk of RA, there are many studies which support the
potential for familial inheritance to play a role in the susceptibility of a patient to develop
rheumatoid arthritis.1 Several genes have been identified as possible ties to RA. Major
Histocompatibility Complex (MHC) genes, which consist of three separate classes of “HLA-X,”
are thought to be one of the genomic indicators of RA.1 The HLA-DRB1 gene is one of the
Human Leukocyte Antigen (HLA) gene complexes whose role is to encode for MHC class II
antigen-presenting molecules.6 MHC molecules, as described in the Immune System section, are
antigen-presenting molecules responsible for the relationship immune cells have with peptides
on the outside of antigen presenting cells (APCs).5 If the protein made by HLA-DRB1 holds a
peptide that the immune cells do not recognize it, they signal for an inflammatory response in
order to rid the body of the foreign antigen.7 This cascade of events beginning from the MHC
gene is therefore critical in anti-citrullinated protein antibody (ACPA) positive patients because
these autoantibodies are unrecognized by the body and trigger an inflammatory immune
response.1 The role of gene expression in RA pathology is described further in the section Gene
Expression for RA.
Biomarkers are measurable indicators of normal healthy processes or pathogenic
operations that can be used to detect rheumatoid arthritis.7 Two biomarkers, anti-citrullinated
protein antibodies (ACPAs), as mentioned previously, and rheumatoid factor (RF) play a
significant role in determining the probability of developing RA and its severity.7 Over 75% of
RA patients express these biomarkers, hence making them a lead indication for RA.1 High levels
of RF, in particular, indicate the risk for developing aggressive rheumatoid arthritis that greatly
limits joint functionality.7 ACPAs develop as ACPA-positive or negative, the positive indicating
a patient may develop more bone erosion and severe disease progression in comparison to
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ACPA-negative patients.7 ACPAs are perpetuated by environmental factors such as smoking.7
RA proves difficult to treat since individual patients experience varying levels of inflammation,
locations of RA and severity of pain thus the analysis of biomarkers such as autoantibodies, like
ACPA and RF, help health care providers create treatment plans and predict the success of said
treatments for each individual case of RA.2,13 Due to the very nature of biomarkers, however,
they alone cannot be taken as proof for susceptibility to the autoimmune disease RA as they
indicate other autoimmune diseases or infections as well.7 Nonetheless, research has indicated
that in increase in autoantibodies ACPA and RF are highly indicative of future RA
development.2
A review published by C. Croia et. al. disclosed a list of the most likely environmental
factors that contribute to RA, as described in any 2019 articles published on RA. Amongst the
list were factors such as smoking, dietary habits, obesity, infections and others.1 Obesity was
shown to correlate with increased risks of RA for women.1 This correlation is thought to be
caused by adipokines such as leptin which are cytokines released from adipose tissue.1 Leptin
may, in fact, be a player in inflammatory response and bone erosion.8 While obesity has been
shown to correlate with an increased risk of RA, cigarette smoking nearly guarantees
development of RA.1 Studies have indicated that cigarette smoking is the most pertinent external
environmental factor to prompt RA.1 In fact, mouse models exposed to cigarette smoke (CS)
condensate expressed arthritis one day after exposure.1 However, the mechanisms effected by CS
are uncertain. Nonetheless, there appears to be a strong positive correlation between smoking
and the risk for rheumatoid arthritis. The list of factors that contribute to the potential for one to
develop rheumatoid arthritis is extensive however, so there is still great debate amongst the
scientific community as to the causes and foolproof indicators for RA.15
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Gene Expression
Rheumatoid arthritis is largely considered a genome-based and environmentally
influenced autoimmune disease.3 Current studies discovered the HLA-D1 gene clearly partakes
in RA morbidity, however its influence on the disease is yet to be fully understood.1 Genomewide association studies (GWAS) have indicated there are over 100 loci (genes) that are in
association with an increased risk of RA.1
HLA, human leukocyte antigens, are MHC class II surface receptors which are encoded
by the HLA complex present on the sixth chromosome in humans.1,16 Three classes of HLA
exist, and they are all glycoproteins bound to the cell surface.1 Class I HLA and Class III assist in
the process of peptide presentation inside the cell and play a role in the complement system
activation, respectively.1 HLA class II is the lynchpin for displaying peptides on the outer surface
of APCs.1 Without HLA class II it would be an anomaly for T helper CD4+ T cells to be
activated, thus preventing a well-rounded immune response.1
ACPA, an autoantibody and indicator for the onset of RA, is tested in potential RA
patients and determined as either present or absent.1 Prior research once indicated there was a
difference in genetic susceptibility for ACPA-positive patients as compared to ACPA-negative,
but this has since been disproven showing no difference in the heritability of RA when studied in
twins.1 The severity of disease manifestation, however is indicated by a APCA-positive test.1
Citrullination, the “C” in ACPA, is a posttranslational modification that occurs when a charged
arginine is replaced by a neutral citrulline on self-proteins (proteins which ordinarily abide in the
body).1 The variable region of these citrullinated antibodies have unique N-linked glycans
(especially on ACPA-IgG) which is likely the physical difference between ACPAs and
nonpathogenic antibodies.1 Specifically generated by citrullinated B cells, ACPAs react with
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citrullinated autoantigens within the blood and articular cartilage.1 For instance, citrullinated
fibrinogen is normally present within the blood plasma, however during inflammation events the
levels of citrullinated fibrinogen increases nearly threefold.17 This autoantigen glycoprotein
complexes with ACPA to stimulate Fc𝛾 receptors on macrophages. Fc𝛾 receptors then signal for
the release of TNF-𝛼, a proinflammatory cytokine, thus eliciting an immune response.1
Therefore, ACPA leads to an intensified and autoreactive response, all beginning with the
expression of the HLA-DRB1 gene, as depicted in Figure 5.1

Figure 5: A detailed analysis of how HLA-DRB1 gene expression interacts with the
complex autoimmune response pertaining to RA.1
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HLA Genes
HLA is a relevant gene to RA pathogenicity because of its relationship with ACPAs.1
HLA expression is similar in both young-onset and normal RA, which indicates its role is of
unique importance regardless of age.1 HLA-DRB1 is associated with positive ACPA RA, in
particular.1 There has long been a hypothesis concerning three amino acid sequences
[70QRRAA74, 70RRRAA74 or 70QKRAA74 (where R is Arginine, A is Alanine and K is
Lysine)] which are commonly referred to as the “shared epitope” (SE).1 The presence of these
SE in the HLA-DRB1 gene is thought to allow for self-antigens to be presented to T
lymphocytes.1 Approximately 75% of patients with RA have the HLA-DRB1 SE allele.18 Indeed,
RA development is three to five times higher in patients with the SE allele than in those who do
not.1 There are several loci within the HLA class II region that have been shown to play a role in
RA: HLA-DP, HLA-DQ, and HLA-DR.1 HLA-DRB1 shared epitope is also strongly associated
with ACPA-positive RA and the overall presence of autoantibodies.1 HLA-DRB1 SE also
corresponds with increased mortality, though interestingly SE is most common in men, not
women which is the population group which is normally most susceptible to RA.1 Perhaps one of
the most interesting findings concerning HLA-DRB1 SE is its relationship with cigarette
smoking (CS). This environmental factor, coupled with HLA-DRB1 SE, positively correlates
with an increase in autoantibody production in RA.1 Specifically, there are six exons on the
HLA-DRB1 gene.1 (This is the location on a gene where the information for coding a protein or
peptide is stored.1) Exon 2 is where the antigen recognition site for coding antigen recognition is
housed, therefore Exon 2 in the HLA-DRB1 gene is crucial to the potential changes in immune
recognition that leads to RA.1
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HLA-DRB1 is not the only gene thought to influence or be influenced by RA
pathogenesis.1 The list is quite exhaustive (over 100 genes have been identified), but there is a
handful of genes which are more noteworthy than the others.18 CD97, FYB, CXCL1, IKBKE,
CCR1 are genes which play a direct role in immune response.18 CD97, CXCL1, C3 AR1, CCR1,
and LYZ induce inflammatory responses, and C3 AR1, CCR1, PLN, CCL19, PPT1 are involved
in homeostasis.18 Some of these genes, such as CXCL6 and CXCL1, are part of the same C-X-C
motif rather than two entirely distinct genes.18 Each RA-related gene plays an intricate role in
RA as expressed in the supporting literature extensively.1,18,19 CXCL1, for instance, is known to
powerfully attract neutrophils in the synovial tissue and fluid of RA.1 This heavy attraction is
triggered by TNF-𝛼 or IL-1𝛽 both being key players in RA.18 Studies such as the microarray
depicted in Supplemental Data 1 have been shown as an effective gene analysis tool.20 Indeed,
much more research is needed in the area of gene expression for RA considering the vast
implications even a single gene may have on the various pathways involved in RA
pathogenicity.18,20
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Current Treatments
Treatment Course of Action
Symptom-based treatment options are available for patients with RA. Since each case of
RA can vary in pain intensity, bone degradation and an individual’s response to pharmaceuticals,
there are a slew of treatment options. Nonsteroidal anti-inflammatory drugs (NSAIDS),
corticosteroid medications, and various forms of disease-modifying antirheumatic drug
(DMARDs) agents are the most common forms of drugs used to combat the symptoms.22 Since
most patients experience joint damage as early as two years into their initial diagnosis, early
treatment in the beginning months of diagnosis is of the utmost importance.5 Physicians
prescribe drugs depending on the severity of each case in order to control inflammation, and
potentially achieve remission for their patients if the treatment is prompt and effective.22
In addition to d25rug intervention is the importance for patients to be educated about the
importance of exercise and physical therapy.22 Weight bearing exercises have been shown to
particularly aid in the retardation of RA symptom onset.22 According to studies of biomarkers,
RA is perpetuated by factors such as obesity and smoking, so patients with RA who take
preventative measures against these conditions and habits will only benefit in the long-run for
their disease remission outcome.7,22
Unfortunately, due to the autoimmune nature of RA and the severity of its progression, as
well as the intensity of immunosuppressing drugs, many patients are backed into a metaphorical
corner. They are crushed by the trifecta of severe pharmaceutical side effects, grating pain or
living in a constant state of immunosuppression. It is for these reasons that one of the greatest
current struggles in treating RA is the ineffectiveness of drugs for long-term remission.22 Given

24
RA has both genetic and environmental factors which contribute to its development, it is
imperative to assist patients in taking preventative measures against this disease.
The European League Against Rheumatism (EULAR) has compiled a three phase,
multifaceted set of 10 recommendations for how to treat RA as well as a pointed, target-to-target
approach for optimal patient outcome.22 Supplemental Data 3 depicts said recommendations.22
The treatment process is split apart in three phases, each dependent on how a patient responds to
the selected pharmaceuticals and if a target outcome has been achieved.22 Methotrexate, an
immunosuppressive antimetabolite DMARD drug, is often suggested as the initial treatment for
RA, however if a patient reacts poorly to methotrexate or other conventional synthetic DMARDs
(csDMARDs), alternative DMARDs can be prescribed.22 Either of these treatments can be paired
with short term, low dose glucocorticoids.22 If these combinations fail to aid in decreasing
inflammation and pain after six months, a patient enters phase II.22 Characterized by the addition
of biologics, otherwise known as biologic DMARDs, treatments with a targeted DMARD “TNFinhibitor” or an “IL-6 inhibitor” in this phase heightens the intensity of drugs used to fight
progressing RA symptoms.22 This pharmacological approach was discovered largely by
analyzing the effects of HLA-DRB1 SE in RA patients.1,16 If a patient moves into phase III
recommendations, alternative biologics are prescribed.22 A Janus kinase inhibitor (JAKinhibitor) is a recent discovery and last resort for treatment options.22 Importantly, if an
individual experiences positive results from any of the treatment in the various phases, the drug
regimen is not discontinued, rather it is repeated indefinitely in order to maintain antiinflammatory effects, decrease pain and potentially increase quality of life.22 The hurdle for
long-term remission in so many RA cases however is the ability of the immune system to create
antibodies against the biologics introduced to it.
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Glucocorticoids
During the early disease state of RA, glucocorticoids (GC) may be utilized in order to
control inflammation, swelling and relieve pain quickly.22 GCs are a subgroup of steroids,
therefore, their use is most effective for short term, 3-4 month, periods and are not recommended
to be used longer than that time frame due to their harsh side effects and possible
comorbidities.22,23 Therefore, GCs can be replaced by or paired with DMARDs for long-term
inflammation dampening.22 GCs are effective against inflammation due to their mechanisms of
action by inhibiting B and T cells.23 GCs suppress proinflammatory molecules in a process
known as transrepression.22 The opposing but simultaneous action of GCs is transactivating antiinflammatory molecules.22,23 Transactivation is thought to cause adverse effects within the body
during chronic use of GCs.22 A few of the adverse side effects include weight gain, fat
redistribution such as a buffalo hump as shown in Figure 7 (buffalo hump source), osteoporosis,
fractures, cardiovascular effects such as atrial fibrillation, flutter, and heart failure, increased risk
of infection, and lastly, hyperglycemia.21,23,24 Patients are more likely to experience serious

Figure 6: Buffalo hump, or the accumulation of adipose tissue on the
neck and trunk of a male rheumatoid arthritis patient. (View is both
lateral and posterior).21
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effects such as these if GC use is prolonged, so they are rarely prescribed on a long-term
treatment regimen.22,23 Disease-modifying antirheumatic drugs can therefore be prescribed in
conjunction with or in place of glucocorticoids.22,25
Methotrexate
Methotrexate (MTX) and other conventional DMARDs dampen the inflammatory
response via several modes of action including downregulating the production of TNF.22
Methotrexate is one of the most commonly prescribed conventional synthetic DMARD
(csDMARD) though its high dose related side-effects are severe and can be life threatening.22,25
The milder side effects of low-dose MTX are WBC and platelet deficiency, headaches,
gastrointestinal complications, but many of these can be subdued by folate supplementation.22
Folate supplementation is necessary because MTX treatment causes the body to dispel it at
higher rates than in normal function.26 This affects a person as a whole because folate helps
prevent anemia, aids in tissue growth and cell action and is all-around essential to normal bodily
functioning.26 MTX can be replaced with other DMARDs such as leflunomide,
hydroxychloroquine or sulfasalazine if a patient reacts poorly to MTX; these drugs express
similar success to MTX.22
The process of determining which drug is most effective for an individual can be long
and grueling. The effects of MTX are often not experienced until 12 weeks into consistent oral
ingestion of the drug either once a day or weekly depending on recommendations.22 After 24
weeks of drug treatment, then a decision can be made as to whether or not MTX is assisting in
remission of RA.22 This drawn-out effect thus can leave many patients frustrated with their
treatment and lead them to discontinue the drug unsafely.22
Tumor Necrosis Factor-Alpha Inhibitors

27
Tumor Necrosis Factor-Alpha Inhibitor (TNFi) is unique compared to GCs because they
are antibodies which target tumor necrosis factor (TNF) within the immune system.22,27 TNFi is a
biologic meaning it is composed of large antibodies which were derived from living cells in a
laboratory setting.28 Biologics can be large or small molecules and are not always antibodies,
regardless, they always target either a specific genotype or protein receptor.28 In the case of
TNFi, it targets the latter.28 Recall, TNF signals for proinflammatory cytokine production, such
as IL-6, and inhibits Treg cells.19 There are currently five TNFi available for treatment and while
each can be utilized to combat various diseases all can be applied to RA treatment, the most
common of which is Infliximab.22,27,29 TNFi acts to hinder TNF by binding to its correlating
receptors present on nearly all types of cells other than erythrocytes.27 The two receptors to
which TNF normally binds are so1TNF and tmTNF which signal for inflammatory response and
increased sensitivity to infection, respectively.27,29 The issue with TNFi is its non-selectively.29
TNFi blocks both the receptors TNF normally binds to which is beneficial for anti-inflammatory
effects but of detriment for the ability of the immune system to fight infection.29
IL-6 Inhibitors
An IL-6 inhibitor binds more specifically than TNFi’s.22 This inhibitor prevents the
actions of IL-6, a cytokine abundant in the synovium of RA patients and known for its
proinflammatory activation.22,30 IL-6 may contributes to B-cell differentiation in turn producing
autoantibodies such as RF and ACPA.30 IL-6 also induces differentiation of T-cells into IL-17
secreting Th17 T helper cells thus preventing Treg divergence.31 To add insult to injury, quite
literally, IL-6 may encourage synovial fibroblast changes and osteoclast activation leading to
further degradation and annihilation of cartilage and bone matter.30
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IL-6 inhibitors are most commonly monoclonal (synthetically produced antibodies) that
bind to both membrane-bound and soluble IL-6 receptors, hence blocking the option for the cell
to signal for others hence preventing an increase in inflammatory response.17 The common
prescription IL-6 inhibitor is Tocilizumab.30(p6) IL-6 continue to be normally produced by the
innate immune system cells such as macrophages, and neutrophils, as well as adaptive immune
B-cells, but they are rendered inactive when an IL-6 inhibitor binds to its receptors.32 Unlike
other inflammatory diseases whose inflammation is characterized by TNF, IL-6 is thought to
indicate inflammatory response and the pathogenesis of RA.32 In terms of treatment with IL-6
inhibitors, a patient may be able to receive intravenous drip infusion once every four weeks with
dosage depending on clinical response. The benefit of this treatment is that its impact, whether
null or positive, is observable more quickly than TNFi or MTX treatment options.30,32
JAK-Inhibitors
The final resort for many RA courses of action is a Janus-Kinase Inhibitor. Drugs such as
tofacitinib are JAK-inhibitors, targeted, synthetic DMARDS (tsDMARDS) with a mechanism of
action that blocks tyrosine kinase.22 JAK are tyrosine kinases present in the cytoplasm.22 There
are 90 forms of Jaks which fall into four categories: Tyk2, Jak1, Jak2 and Jak3.33The JAKs
pertinent to RA play an intricate part in signal transduction to the nucleus from interleukins and
act as downstream mediators for pro-inflammatory cytokines such as IL-6.22,33 This downstream
effect is possible because when JAK and cytokines bind, phosphorylation of signal transducer
and activator of transcription (STAT) molecules occurs (hence the “kinase” characteristic of
JAK).22 The phosphorylated STATs then dimerize and can enter the nucleus leading to increased
signaling for inflammatory response- a system that is expressed in Figure 7 (Janus Kinase
inhibitors source).22 The Jak/STAT pathway is often utilized by cytokines to exert their effects
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and therefore JAK has become a promising target for recent therapeutics.33 Concerning RA, the
two available drugs target JAK1/JAK2 or Jak1/JAK3, specifically.33 Tofacitinib blocks Jak1 and
Jak2 thus preventing Th17 cells from generating. This action prevents the production of a
number of pro-inflammatory cytokines which would otherwise be activated by the Th17.33

Figure 7: JAK-Inhibition Mechanism. Cytokines bind to receptors, thus eliciting an intracellular
phosphorylation of the tyrosine kinase receptor. STATs are signaled for, phosphorylated by JAKs and
as a result become dimers. STATs play a large role in regulating gene transcription, therefore, JAK
inhibitors target the initial phosphorylation of STATs via JAK. Listed are a number of known JAKinhibiting drugs.33
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Cigarette Smoke and E-Vapor
Cigarette Smoke
Cigarette smoke (CS) has long been considered the leading environmental factor to
contribute to RA pathogenesis.6 Studies indicate that smoking one pack of cigarettes a year,
which is equivalent to 20 cigarettes, increases the likelihood of contracting RA by 26 percent;
this susceptibility only increasing as the number of cigarettes smoked throughout a person’s
lifetime increases.6
Two of the most critical factors for CS exposure as it pertains to RA development are
intensity and duration, though duration is most impactful.6 For instance, an individual who
smokes throughout the course of his/her life is far more likely to be diagnosed with RA than an
individual who chain smoked (consecutively smoked one cigarette after another) cigarettes at a
social gathering once during their youth. However, both duration and intensity do play a role in
RA development.6 Interestingly, autoantibody production in smokers is much higher than
nonsmoking individuals, additionally, even if smokers test negative for RF and ACPA, their risk
for RA is still heightened compared to nonsmokers.6 CS breaks the tolerance the immune system
has for autoantigens naturally present in the body, according to Ishikawa et al., thus triggering
RA development.6 While both RF and ACPA are the most common autoantibodies present in
people with RA, RF is present at higher rates within smokers than nonsmokers, while ACPApositivity increased dramatically in the smoking population.6
The effects of CS are of both short term and long-term detriment. There reaches a certain
point that the damage from chronic CS in ACPA-positive patients can no longer be undone thus
decreasing RA treatment outcomes.6 On the other hand, if a person has ceased smoking for more
than twenty years, the level of ACPA-negativity increases along with improved outcomes for RA
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treatment and potential remission. The potential improvement of RA outcome for smokers in
longtime remission is an implausible outlook for chronic smokers.6 This stark contrast is once
again thought to be due to the importance of duration verses intensity.6 Crucially, CS is not only
detrimental when experienced first-hand, but also in a second-hand, “passive,” capacity.
Children who experience passive CS have indicated a greater risk for RA in adulthood though
this is a tentative correlation and must be further explored.6 This observation further solidifies
the hypothesis that duration and intensity play key roles in how CS influences RA susceptibility.6
Cigarette Smoke Immune Impact
Without question, CS impacts both cellular and humoral immunity, thus inducing a
systemic inflammatory response both via the innate and adaptive immune systems.6 The difficult
factor in CS is the way it impacts the human body is diverse and far-reaching. Direct inhalation
of CS, as well as passive CS, is a known cause or strong factor in many diseases, including but
certainly not limited to, heart disease, stroke, diabetes, lung disease, lung cancer, COPD, sudden
infant death syndrome, and asthma.22 Therefore, to determine the exact mechanisms by which
CS passive or active affects RA is no small feat (Figure 8).23
One repercussion of CS is observed in Th cells acting with skewed effect in RA.6 Th17 in
particular is a cell of interest in RA development due to its active role in signaling for neutrophils
and inflammatory cytokines from other T cells during the early stages of RA.6 As divulged in the
Current Treatments section, many pro-inflammatory cytokines proliferate exponentially during
RA pathogenesis.6 Th17, TNF-𝛼, IL-6, IL-1𝛼/𝛽, and IFN-𝛾 all proliferate at staggering rates,
and have therefore been targets for treating RA via DMARDs such as methotrexate or JAK
inhibitors.6,24 CS becomes a catch-twenty-two when treatment options are analyzed however
since at first glance it would seem as though smokers have many options for pharmaceutical
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treatment due to the increased presence of target molecules for said therapies. CS adds yet
another layer of complexity to treating RA however by negatively influencing the effectiveness
of these drugs.6 Drugs such as infliximab, a biologic DMARD, therefore has little effect on the
disease.6,24

Figure 8: Pathogenesis of Rheumatoid Arthritis. Genetics and environmental
factor interactions for rheumatoid arthritis. Results of this relationship leads to
loss of tolerance of self-proteins such as B and T cells. Transitioning to arthritis
this translates to structural damage of the joints, and other bodily systems.23
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Vaping and E-Vapor Components
Smoking e-cigarettes, commonly referred to by younger generations as “vaping,”
continues to grow in popularity within the United States, and globally.25 Within the last year, a
national study indicated that more than 10% of youths ages 15-17, and 11% of 18-21 year-old
young adults have smoked Juuls.7 This does not include any of the other forms of e-cigarettes
(electronic cigarettes) on the market, of which the CDC indicates there are many.7 Interestingly,
vaping, unlike cigarette smoking, has a large appeal to broad groups of people, therefore, there is
a more nonchalant acceptance of it amongst school-age children, as well as adults, regardless of
their distinctly differing opinions concerning the harms of CS.26 In fact, many young people
realize the harmful effects vaping has been shown to lead to, but the social aspects of vaping
outweighs those facts.26
Ranking from least to most popular for customer consumption, disposable e-cigarettes,
rechargeable e-cigarettes such as Juuls, and tanks or mods are a few of the broad categories
available to “vape” with (Figure 9).25 Juuls are particularly desirable in the eyes of middle and
high schoolers because of their compact size and USB drive appearance which allows for quick
and unassuming storage, however Juuls are a highly effective vessel for nicotine inhalation as
well.25 The benefit to Juuls are that they seem to be less harmful than CS or other e-cigarettes in
term so the carcinogens present within them.7
Figure 9: Various forms of vape devices as described by the Center for Disease Control 25
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Within the vaping industry, each smoking mechanism product appeals to a different
purpose of the user. For instance, disposable electronic cigarettes are the most affordable option
and provide users affordable and speedy mechanism for nicotine.27 Traditional e-cigarettes are
considered a weaker form of vaping.27 Box mods are incredibly popular due to their powerful,
sub-ohm systems. Sub-ohm systems are often set to lower temperatures to allow the user to
deeply inhale the e-vapor aerosol into his/her lungs. These models are more sophisticated than
other vaping options, with complex systems to control various wattage settings, temperature
control options, and are able to hold large amounts of e-liquid.27 These are often the models
utilized by experienced vapers because of their high capacity for release of aerosol, which allows
for various tricks and smoke maneuvers to be performed.27
All of the available e-cigarettes, hereby referred to as vaping devices, share common
generalities in their functions. They produce an e-vapor aerosol (of which contains various
chemicals, flavors or addictive substances) by heating an e-liquid, “juice,” via battery power
producing heat via coils.25
The general consensus on e-vapor aerosol inhalation, referred to as vaping is that it is
considered less detrimental than CS.28 This viewpoint stands as popular opinion since these
modes of nicotine inhalation contain fewer carcinogens than cigarettes for those hoping to quit
smoking cigarettes.25 There are also non-nicotine forms of juice available to be vaped depending
on what type of model is used, and studies have indicated that these do not lead to compromised
bone integrity.28 It seems as though even without the component of nicotine being introduced to
an organism, RA is perpetuated due to the alternative chemicals and toxins within cigarette
smoke.9 On the contrary, research also indicates vaping is likely as detrimental, if not more, than
CS, depending on the model and juice utilized.7,25
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E-cigarette aerosols contain volatile organic compounds, nicotine, ultrafine particles
which are detrimental to the lungs, heavy metals such as nickel, tin and lead, cancer-causing
chemicals, and flavoring such as diacetyl (which is linked to serious lung disease).25 There are
generally fewer carcinogens within e-cigarettes than traditional cigarettes (TC), however, they
are replaced by propylene glycol (PG), vegetable glycerin (VG) and flavoring which masks the
taste of toxins (unlike that of traditional cigarettes TC).29 Table 1 indicates the five most
common ratios for these two liquids alongside the most commonly purchased vape juice
flavors.27,29 Each concentration of vape elicits a different vape experience, thus juices are chosen
based on individual preferences. Additionally, vape juices commonly contain anywhere from 0
mg, 3.0 mg, 6.0 mg, 12.0 mg, 18.0 mg, or 36 mg of nicotine per 1 mL which allows users to pick
and choose their desired nicotine level for many of the juice options currently on the market.28
E-Vapor and Adolescents

Table 1: Vape Juice Breakdown and Various Juice Flavors. VG is a thicker liquid thus eliciting a thicker
more robust vapor with little flavoring. PG, however, is a thinner liquid ideal for flavor carrying and
inhalation felt on the throat. Therefore, vape juice is often purchased and utilized depending on an
individual's user's preferences
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Vaping is a fairly new form of smoking that is everchanging with its growing appeal due
to its hypothetical superiority to CS.30 Though e-cigarettes are hypothesized to be a less harmful
method for TC smokers to quit smoking or improve chronic asthma as well as COPD outcomes,
there is a downside to e-vapor.30 Vaping has gained widespread popularity amongst adolescents
and young adults. According to the American Journal of Preventative Medicine, youths view
tobacco harm on a spectrum ranging based on the vesicle by which it is exposed to the body.31
In 2017, electric cigarettes were the most regularly purchased from of tobacco by middle
school and high school aged adolescents.30 An additional 1.3 million teens began vaping in 2018,
alone. One can only speculate as to how many youths are partaking in vaping in the year 2020approximately 16 million youths is once recent estimate.30 Unfortunately, vaping companies
quickly realized the appeal vaping had amongst youths, and began marketing on social media
platforms, receiving celebrity endorsements, and promoting vaping with cartoon images, sexual
appeal and sleek marketing tactics.30 The perception of vaping being safe was therefore
compounded by the advertising of these companies.30,32 These companies have since been
rebuked and directed to refrain from such forms of advertising, however, the attraction to vaping
lives on amongst middle and high schoolers.30
E-vapor Effects on the Body
Vaping has been shown to greatly affect oxidative stress (OS) due to an increased
generation of reactive oxygen species.30 Reactive oxygen species play a detrimental role in
health, often contributing to pathogenesis of diseases that occur in the respiratory system,
metabolic actions and neurodegenerative diseases.30 Oxygen reactive species are also key players
in the effects of addiction and dependence.30 These species play a role in smoking addiction,
morphine addiction, alcohol and cocaine addiction and methamphetamine addiction.30
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Specifically, vaping could be an influential contributor to depression and suicide, sleep
deprivation and attention deficits, as well as aggressive, impulsive behaviors.30 Ultimately, these
outcomes are not on the list of characteristics commonly associated with the success for the
future generation, therefore, it is imperative to study the true effects of vaping in order to better
understand the long term effects it may have on adolescents.30 Though there are many
contributors to the steady increase in depression and suicide within the United States, TC
smoking is strongly associated with major depressive disorder among teens.30 Similarly, vaping
use is associated with an increase in suicide ideation- as seen by an increase in reactive oxygen
systems and their link to suicide and suicide attempts.30 Beyond mental health, adolescents who
vape have been shown to express lower academic performances than their non-vaping peers.30
Cognitive deficits, memory impairment, attention deficits and alertness, and the disturbance of
the development of the cerebral cortex and hippocampus are all strongly associated with TC
smoking.30 At this point, it is critical to note that both first and second hand smoke from
cigarettes has been shown to effect teenage sleep patterns, sleep deprivation, and therefore poor
academic performance.30 There needs to be extensive further studies concerning the effects on
adolescent health specifically pertaining to e-vapor, however. One study indicated the effects of
vaping was not, in fact, from the vapor itself, but rather the effects of nicotine in the aerosol.30
Yet another study contradicts that data and indicates that oxygen reactive systems increased after
e-vapor alone.30 Due to the vast options available for vaping juice flavors, nicotine or nonnicotine content, as well as the density of the vapor and aerosols, countless studies with various
combinations could be performed.30 Lastly, long term studies must be performed to analyze the
long term effects of vaping on teens and young adults; only minimal research has been
performed in this area, pertaining to less than four years after vape exposure.30
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The general population often considers smoking TC or e-vapor with their potential effects
on respiratory health.33 This association is well founded for TC, while the little research
conducted on e-vapor effects is indicative of strong negative effects.33 One study discovered that
the summer of 2019 held a tremendous upward trend of vaping-induced lung injuries (EVALI).33
In particular, vaping THC (tetrahydrocannabinol) correlates strongly with lung injuries; these
correlations do not have bias impact based on age bracket. Whether young or mature adult, the
effects of vaping THC specifically have proven to be detrimental.33 Young males who vape have
been shown to experience fever, chills, headaches, chest pain, coughing and shortness of breath.
Correspondingly, gastrointestinal issues such as pain, nausea and vomiting are common.33 The
effects of e-vapor are characterizable even after two days of exposure; acute lung injury, diffuse
alveolar damage and organizing pneumonia are a few of the quickly onset conditions perpetuated
by vaping.10 In conjunction with these disease onsets, chest CAT scans indicated ground-glass
opacities (Figure 10).10
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In comparison to TC, there is little data on the true physiological effects of e-vapor via
the newest forms of e-cigarettes known as vape pens, mods or tanks. This lack of data leaves
much to be desired in terms of the repercussions of vaping- particularly its effects on the next
generation. With the increasing appeal to vaping due to unique smokable flavors, and diverse
tricks and purposes behind each type of vaping, the adolescent population continues to consume
this product with minimal evidence as to how it is impacting their health days, months and
decades from now.

Figure 10: Ground-glass Opacification. CAT scan reveals normal lung (right) versus
ground-glass opacification (right). Ground-glass opacification within the lungs is
common in patients with histories of chronic smoke inhalation, such as with vaping.10
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Laboratory Research Proposal
Rheumatoid Arthritis is the leading form of arthritis, as well as one of the most prevalent
autoimmune diseases. Likely initiated by gene expression abnormality, as well as environmental
factors such as cigarette smoking, and potentially e-vapor, RA pathogenesis is complex and
treatment plans complicated. Though this disease is most common amongst women who are
forty years of age or older, RA susceptibility has been shown to increase with CS exposure.
Since vaping was first introduced in 2007 it has become one of the most popularly consumed
form of nicotine products on the market. In particular, vaping has a large appeal amongst
adolescents. Cigarette smoking has been shown to increase the likelihood of RA induction
exponentially, therefore there may be a similar connection between RA susceptibility and
inhalation of e-vapor. Little research has focused on the effects e-vapor may have on the body;
therefore, the need arises for this novel study. Primarily, studies as to whether or not vaping
worsens the progression of RA must be explored; furthermore, the HLA-DRB1 gene expression
pathway, as well as autoantibody (RF and ACPA) proliferation should be investigated since
these factors are key players in CS exposure and RA pathogenesis.
Specific Aims
The objective of this research proposal is to determine the potential effects of vaping on
adult susceptibility and the pathogenesis of rheumatoid arthritis. Moreover, the effects of chronic
e-vape inhalation in adolescents and young adult will be analyzed to determine in order to
determine a potential increase in rheumatoid arthritis onset later in life. These experiments will
be carried out in arthritis induced mouse models.
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Preparing Arthritic Mouse Models
All of the mice will be treated according to the appropriate handling of vertebrate animals
as laid out by national guidelines and study protocol and kept within individually ventilated
cages in 12-hour light/dark cycles. Likewise, food and water will be available to the animals ad
libitum.34 They will also be acclimated to the nose-only exposure chamber prior to experimental
vapor exposure. The background genome for both the experimental, sham and control groups of
this experiment are C57Bl/6 mice. Historically, active immunization causing collagen induced
arthritis most closely resembles that of RA within mouse models, so this will be induced in the
mice. At 8-10 weeks of age the mice will be injected with a 100 ug tail base injection of CII
dispersed in complete Freunds adjuvant (CFA) at day zero.35 This method was chosen because
CFA allows for a water-in-oil emulsion of antigens that act upon the synovium of the joints.36 At
day 21, these mice will receive a boost of another 100 ug CII of incomplete (IFA) to ensure
proper induction of arthritis via plasma cell activation.35
CRISPR-CAS9
Discovered in 1987 and further understood in 2007, CRISPR-Cas9 is a new technology
based on a system naturally found within bacteria to ward off viral infections.37 Two short RNA
chains form a complex with the Cas9 nuclease (DNA cutting) protein.37 This complex allows
Cas9 to identify the portion of the viral DNA that is detrimental to the bacterium via a guide
RNA.37 This specific portion of DNA is then cut from the genome and replaced with a target
RNA strand. If the match is completed, then the DNA is cut, forcing the cell to begin the repair
process.37 Due to errors that occur in the repair process, however, the gene which CRISPR
interfered with becomes inactivated, allowing the observation of the function of a now disabled
gene.37 This technology is applicable in any genome, even humans, and certainly mice, therefore,
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it will be utilized within Specific Aim II in order to study the downstream effects of silencing
HLA-DRB1.37
Specific Aim I: Vaping worsens Rheumatoid Arthritis.
This aim primarily seeks to lay the foundation for all following experimentations.
Cigarette smoking has long been considered the strongest environmental factor to contribute to
rheumatoid arthritis (RA) induction. The pathway of said influence has yet to be solidified,
however, with the HLA-DB1 pathway presented as the most likely expression pathway for the
immune changes that ultimately lead to onset of RA. Therefore, based on the most readily
available research, this proposal hypothesized that e-vapor and its components may follow a
similar pathway for RA induction as CS. Regardless of pathway however, it is proposed that
vaping will induce more severe RA symptomology than non-vape exposed mice. There is a great
need for this particular study due to the exponential rise of popularity for vaping amongst
adolescents and young adults. The trend of vaping has only continued to grow since it was first
introduced 2007, with little to no hard data and research on the repercussions of e-vapor.
30 C57Bl/6 CIA mice will be equally split between two groups of experimental mice.
Additionally, the sham and control groups will consist of 10 mice each. The experimental and
sham groups will be placed on an inhalation regimen for CS, e-vapor and filtered air,
respectively via a nose-only aerosol exposure system Figure 11.28,34,38 The experimental mice
will be exposed to nose-only inhalation for up to 4hours/day, 5 days a week (a total of 14 days)
in order to mimic chronic CS/e-vapor/filtered air inhalation.28,34,39 Conversely, the animals will
be allotted time to acclimate to the nose-only inhalation and therefore exposure time will
increase from 1 to 4 hours by one hour increments for the first four days of treatment.40 The mice
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will be exposed to an average of one puff of smoke/vapor per 30 seconds, with a 3 second puff
duration.40 The protocol for exposure is carried throughout Aims I-III.
Mice exposed to CS will inhale 3R4F Kentucky reference cigarettes, as these are
commonly utilized within CS studies.35 E-vapor mice will be exposed to a 50PG/50VG/4%
nicotine vapor based on weight consistent with a previous study concerning vapor effects.35 The
mode of vape utilized will be via a SMOK RPM 80 POD MOD which is known to be the middle
ground mod style for beginner and expert vaping individuals since the goal of this proposal is to,
as accurately as possible, analyze the impact of vaping as it is performed by adolescent
consumers in the future aims. The specific dimensions and features of this mod can be found in
Supplemental Data 3.41

Figure 11: Nose-only Aerosol Exposure System. Utilized to standardize the inhalation
and exposure time of mice to the various experimental smokes (CS, e-vapor, filtered
air). Each mouse is housed within an individual tube with its nose exposed only to the
central chamber which is pressure controlled to allow even distribution and
concentration of the aerosols from attached generators.28
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Several studies have been conducted concerning the effects of simplistic e-cigarettes, but
little to no research has been performed in the area of the most common forms of vaping to date.
The central hypothesis for this experiment is that RA expression in both the CS and
vaping group is affected, while it is not affected in the sham and control models. This will be
determined by using a clinical arthritis score of a possible 28 points, paw volume, ankle
thickness measured via caliper and ELISA to determine ACPA and RF autoantibody levels
within blood serum and synovium.35,39,42 These results would indicate not only a solidification of
numerous previous studies pertaining to the effects of CS, but also the potential correlation
between vaping exposure and a perpetuation of RA in the CIA mouse models.
Specific Aim II: To determine whether RA is worsened when exposed to vaping in HLADRB1 knockout (KO) models. The C57B1/6 CIA mouse model, and a CRISPR-Cas9 modified
mouse model will be used, respectively. Therefore, the groupings for this experiment will be as
follows: 15 C57Bl/6 CIA mice with nose-only exposure to vape, 15 C57B1/6 CIA, HLA-DRB1
KO mice exposed to e-vapor, 15 sham mice inhaling filtered air via nose-only exposure, and 10
control C57Bl/6 mice.
The levels of autoantibody proliferation will be measured before and after treatment via
ELISA, RA symptomology analysis will follow suite to Aim I protocol, and a micro assay will
be performed to yield data on gene expression. In order to study the effects of HLA-DRB1 in
experimental C57Bl/6 mice with CIA, micro arrays will be utilized following the protocol
previously stated.43
The perspective outcomes for this aim are to see a significant increase in autoantibody
presence within the synovium and blood serum of mice exposed to vapor. This promising result
would advance the current hypotheses that autoantibodies are a necessary prerequisite to RA
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pathogenesis. Addedly, one would anticipate the HLA-DRB1 manipulated upregulation to
worsen RA, regardless of a vapor-less exposure. Though this particular focus of the study may
prove unsuccessful in the desired results of HLA-DRB1 pathway upregulation triggering RA
pathogenesis, the results would be of benefit since this would create opportunities to pursue
alternative pathways for RA activation.
Specific Aim III: Lastly, the long-term effects of vaping on adolescent mice must be
analyzed. There are currently no longitudinal studies concerning the effects of vapor on
adolescent growth, development, and later the potential onset of RA. Due to the increasing
popularity of vaping amongst middle school and high school aged students, this study is
imperative to the health of the future generation. This long-term exposure study will be
performed on adolescent CD57Bl/6 mice ranging from the juvenile age of 2 to 3 weeks of age
continuing in observation until they reach 4 months of age.
The experimental groups will be separated based on the longevity with which they are
exposed to vapor. The first set of 15 CD57Bl/6 mice will be exposed for 14 days. After which
they will be analyzed for autoantibody production, as well as the same criteria for RA onset as in
specific aim I. Another experimental group of 15 CD57Bl/6 mice will be exposed to nose-only
aerosols for two months, with the final 15 mice experiencing inhalation of vape for the full 4
months to mimic chronic vaping tendencies. The control and sham groups remain the same as
former experimentations have listed, except for their juvenile rather than adult state. Each of the
experimental groups will be observed daily during the first two weeks of exposure, then then
biweekly until they reach 6-8 months of age.
In the final analysis of these experimental groups, the proposed results would
demonstrate not only an elicitation of RA, but also characteristic increases in its expression and
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symptomology due to chronic inhalation of vaping aerosols within the juvenile mice. If such
results are uncovered, this translates to a potentially severe health outcome for teens and young
adults who chronically smoke using e-vapor mechanisms such as the SMOK RPM 80 mod
utilized in this study. The exponential increase in vaping since it was first released in 2007 for
public purchase could be setting up this next generation of young people for higher rates of RA
susceptibility when they reach their mid to late adulthoods. Not only that, but perhaps this RA
induction due to vaping will cause excruciating and escalated pathogenicity of the disease state.,
as CS has been hypothesized to do.
Experimental Pitfalls and Future Aims
These experiments are anticipated to shed light on the relationship between e-vapor and
the induction of rheumatoid arthritis as it pertains to adult and juvenile mouse models. Be that as
it may, there are number of pitfalls within this proposal. The first major pitfall is in the form of
the vape analyzed within the study. Most notably, standardizing the amount of vapor each animal
is exposed to proves difficult considering how unregulated the manufacturing sector for vape
devices is. Though the SMOK RPM 80 POD MOD may be a sound middle ground between
simplistic and complex vaping apparatuses, it is a small portion of the potential forms of vaping
mechanisms on the market. Due to the vast array of options available for vaping ranging from
PG and VG concentration levels, nicotine content, an endless supply of flavorings, and the
apparatus utilized to create vape, there are multitudes of combinations that need to be explored
regarding the effects of vapor. Furthermore, there is currently no data depicting the longitudinal
effects of vaping (except for a single study which examined the effects of vaping three years
after exposure). Though there are numerous studies on the broad topic of e-cigarette smoking,
few have focused on vaping specifically- thus leaving much to be desired for the field.
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Specifically focusing on the experimental design, ideally, more animal models would be utilized
in order to study this subject matter in a more robust format. Moreover, there certainly should be
a study which focuses on the expression of HLA-DRB1 as it relates to RA. The data on this
genetic pathway indicate strong correlations between this and that of CS, so HLA-DRB1 indepth investigation needed to be further analyzed both in CS exposure and vaping. In the future,
it would prove beneficial to upregulate HLA-DRB1 expression without the presence of vape or
CS in order to enhance results that support the role of this pathway in RA pathogenicity. Lastly,
experiments which primarily focus on passive vaping, rather than direct inhalation of vape
aerosols, would undoubtedly prove beneficial. Since vaping is more widely accepted as opposed
to CS, individuals are able to vape in locations TC smokers are not permitted, thus exposing the
general population to e-vapor. In short, the list of future experimentations concerning the effects
of vaping appears to be ever-growing as the industry continues to grow in popularity, particularly
amongst younger generations.
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Conclusion and Future Aims
Rheumatoid arthritis is the leading form of arthritis globally, and commonly begins its
effects on individuals in their mid to late 40’s.24 Nearly two percent of the global population is
effected by the degrading symptoms of rheumatoid arthritis including, but not limited to, swan
neck and boutonniere joint deformation, pain, inflammation, degreased mobility and decreased
quality of life. 2 There is an array of current treatment options for RA that offer various tactics to
combat the pains of RA, but with short-term and complex treatment plans a cure has yet to be
discovered.24
RA is most often characterized by the presence of autoantibodies in the pre-onset stage of
disease progression ACPA and RF being of highest significance for disease pathogenicity.5
Though these two autoantibodies cannot be utilized as the only formal indicators of RA
induction, they are the most common signs for RA onset and are observed in pre-clinical stages
of the disease.2 Additional indicators such as an increase in fibrinogen synthesis, an increased
presence of TNF-ɑ and IL-6, as well as Th17 cells produced cytokines: IL-17A, IL-17F and IL22 during active RA.2,44 The notable complexity of RA begins with the conundrum of what the
initial step of RA truly is. There is large “chicken or the egg first issue” in terms of whether
autoantibodies or self-reactive T-cells and their related cytokines are the initial perpetrators to
RA induction.6 However, there is large scientific consensus considering the genetic and
environmental factors which contribute to an increased susceptibility to RA.
Firstly, the HLA-DRB1 pathway is thought to be the primary pathway for genetic
expression which leads to the increased proliferation of autoantibodies such as ACPA and RF.1
Secondly, the environmental factor of cigarette smoking is the most widely accepted external
contributor to an increased propensity towards developing RA, regardless of gender.6 CS in
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particular is hypothesized to be the trigger which causes the immune system to lose its selftolerance and thus lead to an autoimmune attack against itself.9 The exact mechanism for how
this occurs is still uncertain, however. Additionally, the HLA-DRB1 gene and its related pathway
is the most noteworthy genetic potential for RA influence; it is not the exclusive pathway for
how RA may arise from a genetic perspective.1 Due to the many factors which perhaps lead to an
increased vulnerability to the inclination of RA development, the need arises for further
determination of the mechanisms behind rheumatoid arthritis pathogenicity. Given the many
questions concerning how an individual may be predisposed or superimposed to RA due to
environmental agents, as time continues, new environmental factors may play a role in RA.
Therefore, the recently introduced form of smoking known as e-vapor, “vaping,” may be yet
another powerful contributor of future RA generation.7,31
Vaping is most commonly utilized by adolescents and young adults.7,33 Since the data on
the longitudinal effects of vaping has yet to be collected beyond a three-year time period, there is
an imperative need for the long-term detriment vaping may cause- including potentially leading
to RA, as seen with chronic cigarette smoking.10,33 Therefore, the experimental proposal within
this thesis focused on not only the potential connection vaping has with triggering RA, but also
chronic vape exposure and how it effects RA severity, in respect to both the HLA-DRB1
pathway and HLA-DRB1 knockout mice. There are heaps of future experiments which could be
performed specifically focusing on the numerous forms of vaping, but first-and-foremost there
must simply be any form of these experiments performed. Second-hand vaping, analysis of
alternative pathways for RA expression, and comparisons between the effects of vaping on adults
versus children are but a few to consider. Experiments on vaping must be performed due to the
drastic increase in popularity it has amongst youths. In 2018, 1.3 million middle and high school
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students were vaping, however, just a mere two years later, over 16 million adolescents within
the United States have tried or consistently vape.7,25 Consequently, the future generation
perceives vaping as the healthier alternative to cigarette smoking, but the effects of vaping on
bodily health is largely unknown. Id est, though vaping is seen in a fairly positive light by many,
it may be as deleterious as CS in terms of its short and long-term health consequences.
Upon final analysis, rheumatoid arthritis is one of the most common autoimmune
diseases within the United States, and globally. Though there are many potential contributors to
an increased susceptibility for inducing RA, two main factors must be highlighted: the effects of
one’s genetic predisposition, and the environmental factor of cigarette smoke. With the vaping
industry only continuing to gain appeal amongst adolescents, the question is raised as to if, and
how e-vapor potentially contributes to the onset of rheumatoid arthritis as these individuals reach
late adulthood. Without studies which focus on this potential connection to RA pathogenicity,
there may be a population which is voluntarily increasing their vulnerability to rheumatoid
arthritis.

51
References
1.

Wysocki T, Olesińska M, Paradowska-Gorycka A. Current Understanding of an Emerging
Role of HLA-DRB1 Gene in Rheumatoid Arthritis–From Research to Clinical Practice.
Cells. 2020;9(5):1127. doi:10.3390/cells9051127

2.

Atzeni F, Talotta R, Masala IF, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Biomarkers
in Rheumatoid Arthritis. :5.

3.

Firestein G, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity.
2017;46(2):183-196. doi:10.1016/j.immuni.2017.02.006

4.

Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid Arthritis: A Brief Overview of the
Treatment. Med Princ Pract. 2019;27(6):501-507. doi:10.1159/000493390

5.

Wigerblad G, Bas DB, Fernades-Cerqueira C, et al. Autoantibodies to citrullinated proteins
induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann
Rheum Dis. 2016;75(4):730-738. doi:10.1136/annrheumdis-2015-208094

6.

Ishikawa Y, Terao C. The Impact of Cigarette Smoking on Risk of Rheumatoid Arthritis: A
Narrative Review. Cells. 2020;9(2):475. doi:10.3390/cells9020475

7.

Chen-Sankey JC, Tan ASL, Moran MB, Soneji S, Lee SJ, Choi K. Sources of awareness,
perceptions, and use of JUUL e-cigarettes among adult cigarette smokers. PLoS ONE.
2020;16(9):1-12. doi:10.1371/journal.pone.0238377

8.

Health CO on S and. Smoking and Tobacco Use; Electronic Cigarettes. Centers for Disease
Control and Prevention. Published September 9, 2020. Accessed September 26, 2020.
https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html

9.

Okamoto S, Adachi M, Chujo S, et al. Etiological role of cigarette smoking in rheumatoid
arthritis: Nasal exposure to cigarette smoke condensate extracts augments the development
of collagen-induced arthritis in mice. Biochem Biophys Res Commun. 2011;404(4):10881092. doi:10.1016/j.bbrc.2010.12.118

10. Mukhopadhyay S, Mehrad M, Dammert P, et al. Lung Biopsy Findings in Severe
Pulmonary Illness Associated With E-Cigarette Use (Vaping)A Report of Eight Cases. Am
J Clin Pathol. 2020;153(1):30-39. doi:10.1093/ajcp/aqz182
11. Immunology: A Short Course. Accessed September 26, 2020.
https://platform.virdocs.com/r/s/0/doc/509181/sp/62159452/mi/262329966?cfi=%2F4%2F2
%2F14%2F10%2C%2F1%3A206%2C%2F1%3A206
12. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. B Cells and Antibodies. Mol
Biol Cell 4th Ed. Published online 2002. Accessed August 2, 2020.
https://www.ncbi.nlm.nih.gov/books/NBK26884/

52
13. Chen M, Daha MR, Kallenberg CGM. The complement system in systemic autoimmune
disease. J Autoimmun. 2010;34(3):J276-J286. doi:10.1016/j.jaut.2009.11.014
14. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. T Cells and MHC Proteins.
Mol Biol Cell 4th Ed. Published online 2002. Accessed August 4, 2020.
https://www.ncbi.nlm.nih.gov/books/NBK26926/
15. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly
inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795-804.
doi:10.1056/NEJMoa1202753
16. Reference GH. HLA-DRB1 gene. Genetics Home Reference. Accessed September 17,
2020. https://ghr.nlm.nih.gov/gene/HLA-DRB1
17. Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and fibrin in hemostasis and thrombosis.
Arterioscler Thromb Vasc Biol. 2017;37(3):e13-e21. doi:10.1161/ATVBAHA.117.308564
18. Ma C, Lv Q, Teng S, Yu Y, Niu K, Yi C. Identifying key genes in rheumatoid arthritis by
weighted gene co-expression network analysis. Int J Rheum Dis. 2017;20(8):971-979.
doi:10.1111/1756-185X.13063
19. Platzer A, Nussbaumer T, Karonitsch T, Smolen JS, Aletaha D. Analysis of gene
expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene
biotypes and co-expression patterns. PLoS ONE. 2019;14(7):1-23.
doi:10.1371/journal.pone.0219698
20. Devauchelle V, Marion S, Cagnard N, et al. DNA microarray allows molecular profiling of
rheumatoid arthritis and identification of pathophysiological targets. Genes Immun.
2004;5(8):597-608. doi:10.1038/sj.gene.6364132
21. Carrese E, Morandi U, Stefani A, Aramini B. Total thyroidectomy in HIV positive patient
with buffalo hump and taurine neck. Int J Surg Case Rep. 2019;61:64-66.
doi:10.1016/j.ijscr.2019.07.020
22. CDCTobaccoFree. Health Effects of Smoking and Tobacco Use. Centers for Disease
Control and Prevention. Published February 9, 2017. Accessed September 22, 2020.
https://www.cdc.gov/tobacco/basic_information/health_effects/index.htm
23. The Pathogenesis of Rheumatoid Arthritis - ProQuest. Accessed September 26, 2020.
https://www-proquestcom.seu.idm.oclc.org/docview/909867083/fulltext/334464093EB4133PQ/1?accountid=439
12
24. Köhler BM, Günther J, Kaudewitz D, Lorenz H-M. Current Therapeutic Options in the
Treatment of Rheumatoid Arthritis. J Clin Med. 2019;8(7). doi:10.3390/jcm8070938

53
25. Health CO on S and. Smoking and Tobacco Use; Electronic Cigarettes. Centers for Disease
Control and Prevention. Published February 25, 2020. Accessed September 26, 2020.
https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html
26. Study Shows New Focus Needed in Anti-Vaping Efforts for Teens & Young Adults.
University of Michigan. Accessed September 26, 2020.
https://labblog.uofmhealth.org/rounds/study-shows-new-focus-needed-anti-vaping-effortsfor-teens-young-adults
27. Goo R. Different Types Of Vapes Explained. Vapebox. Published December 5, 2019.
Accessed September 26, 2020. https://www.vape-box.com/blog/types-of-vapes
28. Reumann MK, Schaefer J, Titz B, et al. E-vapor aerosols do not compromise bone integrity
relative to cigarette smoke after 6-month inhalation in an ApoE–/– mouse model. Arch
Toxicol. 2020;94(6):2163-2177. doi:10.1007/s00204-020-02769-4
29. McConnell M. Types Of Vape Juice. Freeman Vape juice. Published 34:00 700. Accessed
September 26, 2020. https://www.freemanvapejuice.com/blogs/vape-news-andreviews/types-of-vape-juice
30. Tobore TO. On the potential harmful effects of E-Cigarettes (EC) on the developing brain:
The relationship between vaping-induced oxidative stress and adolescent/young adults
social maladjustment. J Adolesc. 2019;76:202-209. doi:10.1016/j.adolescence.2019.09.004
31. Ambrose BK, Rostron BL, Johnson SE, et al. Perceptions of the Relative Harm of
Cigarettes and E-cigarettes Among U.S. Youth. Am J Prev Med. 2014;47(2):S53-S60.
doi:10.1016/j.amepre.2014.04.016
32. DeLauro RL. Text - H.R.293 - 116th Congress (2019-2020): Youth Vaping Prevention Act
of 2019. Published March 1, 2019. Accessed October 6, 2020.
https://www.congress.gov/bill/116th-congress/house-bill/293/text
33. Essa A, Macaraeg J, Jagan N, et al. Review of Cases of E-Cigarette or Vaping Product UseAssociated Lung Injury (EVALI) and Brief Review of the Literature. Case Rep Pulmonol.
Published online June 15, 2020:1-7. doi:10.1155/2020/1090629
34. Koning H, van Oosterhout AJM, Brouwer U, et al. Mouse Protocadherin-1 Gene
Expression Is Regulated by Cigarette Smoke Exposure In Vivo. PLoS ONE. 2014;9(7):110. doi:10.1371/journal.pone.0098197
35. Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in
Mice with Collagen Induced Arthritis.
36. Complete Freund’s Adjuvant (CFA). Accessed October 7, 2020.
https://ehso.emory.edu/research-safety/bars/complete-freunds.html
37. Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9. FEBS J.
2014;281(23):5186-5193. doi:10.1111/febs.13110

54
38. Phillips JE, Zhang X, Johnston JA. Dry Powder and Nebulized Aerosol Inhalation of
Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System. JoVE J Vis Exp.
2017;(122):e55454. doi:10.3791/55454
39. Caplazi P, Baca M, Barck K, et al. Mouse Models of Rheumatoid Arthritis: Vet Pathol.
Published online June 10, 2015. doi:10.1177/0300985815588612
40. Lee KM, Hoeng J, Harbo S, et al. Biological changes in C57BL/6 mice following 3 weeks
of inhalation exposure to cigarette smoke or e-vapor aerosols. Inhal Toxicol.
2018;30(13/14):553-567. doi:10.1080/08958378.2019.1576807
41. SMOK RPM 80 Pod Mod Kit. Accessed October 7, 2020.
https://www.elementvape.com/smok-rpm-80
42. At a glance: Common scores used in rheumatology. rheumatology.medicinematters.com.
Published September 7, 2018. Accessed October 7, 2020.
https://rheumatology.medicinematters.com/treatment/patient-reported-outcomes-/at-aglance-rheumatology-scores/16077860
43. Zhang F, Hu SW, Huang J, et al. Oligonucleotide microarray for HLA-DRB1 genotyping:
preparation and clinical evaluation. Tissue Antigens. 2005;65(5):467-473.
doi:10.1111/j.1399-0039.2005.00395.x
44. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid
arthritis? Curr Opin Rheumatol. 2018;30(2):207-214.
doi:10.1097/BOR.0000000000000470

55
Supplemental Data
Supplemental Data 1: Example of a microarray. This particular example of a microarray
depicts the comparison of osteoarthritis (OA) and rheumatoid arthritis (RA). The original
caption is included to provide context for the significance of this example. Note the RA
specific genes (highlighted in yellow) in both a and b. Experimentation similar to this was
performed in the “Experimental Proposal” portion of this paper.
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Supplemental Data 2: Established by the European League Against Rheumatism (EULAR), this is the
recommended pathway to treatment options for rheumatoid arthritis (RA) and its management. Broken
into three phases, pharmaceutical options include csDMARDs, bDMARD, DMARD, biologic agents, and
JAK-inhibitors.22
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Supplemental Data 3: Mode of Vape Utilized for Experimental Proposal. SMOK RPM80 is considered a
median level vape device due to its 0.4-ohm system, customizable temperature gauge and display screen.
Additionally, this model is not as industrial as other models due to its moderate puff capacity.41

